Login Form

CJC-1295 without DAC

Trade Names: CJC-1295
Chemical Names: Tetrasubstituted Growth Hormone Releasing Factor (1-29)
Routes: Subcutaneous Injection

CJC-1295 without DAC is a synthetic GHRH (Growth Hormone Releasing Hormone) analog that is effective at stimulating the pituitary gland to secrete much larger amounts of growth hormone than normal, also resulting in elevated IGF1 levels. It is a peptide containing a single chain of 29 amino acids. The first 29 amino acids of the 44 amino acid chain that make up our natural GHRH were identified as the biologically active part responsible for stimulating GH release. So these 29 aminos were isolated and the remaining 15 that were useless to growth hormone release were removed. This peptide known as Growth hormone Releasing Factor (1-29), or Sermorelin, was the base peptide used by the pharmaceutical company ConjuChem to create the various CJC GHRH peptides.

CJC1295 w/o DAC has 4 of those 29 amino acids substituted for other amino acids to create a more stable peptide with enhanced bioactivity. This prolongs half-life from under 10 minutes to a much more effective 30 minutes and results in more growth hormone being released from the pituitary.

The CJC GH peptides (CJC1288, CJC1293, CJC1295, CJC1295 without DAC) all perform the same basic function of stimulating growth hormone release, with the differences being variations in half-life and systemic stability after administration. CJC1295 w/o DAC is recommended over the other GHRHs because it has the ideal active life for effective GH release in a pulsatile manner similar to our natural pulsatile release patterns. This allows it to work in harmony with our body without causing rapid desensitization of receptors.

It is administered by subcutaneous injection and the recommended dose for is 1mcg per Kg of bodyweight, (100mcg for a man weighing 100kg). This is the saturation dose, so the more you use over this amount, the less added benefit you will get. The problem with using any GHRH is that they are only effective at releasing GH when somatostatin (which inhibits GH release) is low. If it is used while somatostatin levels are elevated then it will only cause a very slight GH release, so the timing of injections is very important with this peptide.

To overcome this it is recommended to use CJC1295 w/o DAC together with a GHRP (Growth Hormone Releasing Peptide) like Ipamorelin, as the synergy of using them together overcomes somatostatin’s inhibiting effect. The best times for using it are right before bed, right after waking in the morning and post workout, preferably with a GHRP. Combined GHRH and GHRP administration causes a synergistic Growth Hormone release which means that by using them together the whole is greater than the sum of the parts so that 2 + 3 = 10!

CJC1295 w/o DAC is usually supplied in a 2mg peptide vials that need to be reconstituted with bacteriostatic water. It is a fairly fragile peptide and after reconstitution it should be stored in the fridge between 2°C - 8 °C and used within 4 weeks. Unmixed vials should be stored in the freezer if not being used within a few months of the date of manufacture.